Graft-vs-leukemia activity and graft-vs-host disease induced by allogeneic Th1- and Th2-type CD4+ T cells in mice

Hematology Journal

Volumn 2, Issue 2, 2001, Pages 136-144

  Zeis, M ^a   Uharek, L ^a   Hartung, G ^a   Glass, B ^a   Steinmann, J ^a   Schmitz, N ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

Allogeneic BMT; CD4+ T cells; GVHD; GVL; Th1; Th2

Indexed keywords

CD4 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 4;

ALLOGENIC BONE MARROW TRANSPLANTATION; ALLOGRAFT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL LEUKEMIA; BONE MARROW CELL; CELL TRANSPLANTATION; COMPARATIVE STUDY; CONTROLLED STUDY; DEATH; DISEASE SEVERITY; DONOR; DOSE RESPONSE; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; LEUKEMIA CELL; MORTALITY; MOUSE; MOUSE STRAIN; NONHUMAN; RISK ASSESSMENT; T LYMPHOCYTE; TH1 CELL; TH2 CELL; WHOLE BODY RADIATION;

ADOPTIVE TRANSFER; ANIMALS; CELL LINE, TUMOR; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LEUKEMIA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; TH1 CELLS; TH2 CELLS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0035022564     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200087     Document Type: Article

References (31)

1. Treatment of murine leukemia with X-rays and homologous bone marrow
2. Cytokine dysregulation and acute graft-versus-host disease
3. T cell depletion of HLA and haploidentical marrow reduces graft-versus-host disease but may impair a graft-versus-leukemia effect
4. Donor leucocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients
5. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia
6. Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance and allows for persistent antileukemic reactivity without severe graft-versus-host disease
7. Allogeneic NK cells as potent antileukemic effector cells after allogeneic bone marrow transplantation
8. Allogeneic MHC-mismatched activated natural killer cells administered after bone marrow transplantation provide a strong graft-versus-leukemia (GVL) effect in mice
9. Natural killer cells as effector cells of graft-versus-leukemia activity in a murine transplantation model
10. Toxicity and efficacy of defined doses of CD4+ donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant
11. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation
12. Functional diversity of helper T lymphocytes
13. The expanding universe of T-cell subsets: Th1, Th2 and more
14. Lymphocyte responses and cytokines
15. Mechanisms of disease: Graft-versus-host disease
16. Recent advances in graft-versus-host disease (GVHD) prevention
17. Critical role of interleukin-2 in the development of acute graft-versus-host disease
18. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs-host disease
19. Antibodies to IFN-gamma prevent immunological mediated intestinal damage in murine graft-versus-host reactions
20. Transplantation of polarized type 2 donor T cells reduces mortality caused by experimental graft-versus-host disease
21. Polarized type 2 alloreactive CD4+ and CD8+ donor T cells fail to induce experimental acute graft-versus-host disease
22. Cells of Th2 cytokine phenotype prevent LPS-induced lethality during murine graft-versus-host reaction
23. Donor CD4-enriched cells of Th2 cytokine phenotype regulate graft-versus-host disease without impairing allogeneic engraftment in sublethally irradiated mice
24. Interleukin-2 prevents graft-versus-host disease while preserving the graft-versus-leukemia effect of allogeneic T cells
25. Interleukin-12 inhibits murine graft-versus-host disease
26. Differential effects of the absence of interferon-y and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice
27. +, Tc1/Tc2 populations in murine GVL: Type I cells generate GVL and Type II cells abrogate GVL
28. Establishment and characterization of Balb/c lymphoma lines with B cell properties
29. Graft-versus-leukemia activity after bone marrow transplantation does not require graft-versus-host disease
30. The role of purified CD8+ T cells in graft-versus-leukemia activity and engraftment after allogeneic bone marrow transplantation
31. Graft-versus-myeloid leukemia responses following syngeneic and allogeneic bone marrow transplantation